^
Association details:
| Biomarker: | ER Y537N + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
264P - AMEERA-1: Subgroup analyses of phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC)
Published date:
09/13/2021
Excerpt:
This open-label, phase 1/2 study assessed palbo 125 mg (21 days on, 7 off) + amcenestrant in dose escalation (Part C; n = 15; 200 and 400 mg QD in 28-day cycles) and dose expansion (Part D; n = 30; 200 mg recommended phase 2 dose) in ER+/HER2– aBC patients (pts) with ≥ 6 months of prior endocrine therapy....CB was observed for 7/8 pts with Y537S, D538G, E380Q, or Y537N baseline ESR1 mutations...
Secondary therapy:
SAR439859
Trial ID:
